Suppr超能文献

介导盐酸海吡酮(YL-0919)快速起效抗抑郁作用的西格玛-1受体激动剂特性。

Sigma-1 receptor agonist properties that mediate the fast-onset antidepressant effect of hypidone hydrochloride (YL-0919).

作者信息

Ren Peng, Wang Jing-Ya, Chen Hong-Lei, Chang Hai-Xia, Zeng Zhi-Rui, Li Guang-Xiang, Ma Hui, Zhao Yong-Qi, Li Yun-Feng

机构信息

Beijing Institute of Basic Medical Sciences, Beijing, China.

Graduate Collaborative Training Base of Academy of Military Medical Sciences, Hengyang Medical School, University of South China, Hengyang, China.

出版信息

Eur J Pharmacol. 2023 May 5;946:175647. doi: 10.1016/j.ejphar.2023.175647. Epub 2023 Mar 8.

Abstract

The most intriguing characteristic of the sigma-1 receptor is its ability to regulate multiple functional proteins directly via protein-protein interactions, giving the sigma-1 receptor the powerful ability to regulate several survival and metabolic functions in cells, fine tune neuronal excitability, and regulate the transmission of information within brain circuits. This characteristic makes sigma-1 receptors attractive candidates for the development of new drugs. Hypidone hydrochloride (YL-0919), a novel structured antidepressant candidate developed in our laboratory, possess a selective sigma-1 receptor agonist profile, as evidenced by molecular docking, radioligand receptor binding assays, and receptor functional experiments. In vivo studies have revealed that YL-0919 elicits a fast-onset antidepressant activity (within one week) that can be attenuated with pretreatment of the selective sigma-1 receptor antagonist, BD-1047. Taken together, the findings of the current study suggest that YL-0919 activates the sigma-1 receptor to partially mediate the rapid onset antidepressant effects of YL-0919. Thus, YL-0919 is a promising candidate as a fast-onset antidepressant that targets the sigma-1 receptor.

摘要

σ-1受体最引人关注的特性是其能够通过蛋白质-蛋白质相互作用直接调节多种功能蛋白,这赋予了σ-1受体强大的能力来调节细胞中的多种生存和代谢功能、微调神经元兴奋性以及调节脑回路内的信息传递。这一特性使σ-1受体成为开发新药的有吸引力的候选对象。盐酸海皮酮(YL-0919)是我们实验室开发的一种新型结构的抗抑郁候选药物,具有选择性σ-1受体激动剂特征,分子对接、放射性配体受体结合试验和受体功能实验均证明了这一点。体内研究表明,YL-0919能引发快速起效的抗抑郁活性(在一周内),而选择性σ-1受体拮抗剂BD-1047预处理可减弱这种活性。综上所述,当前研究结果表明,YL-0919激活σ-1受体以部分介导其快速起效的抗抑郁作用。因此,YL-0919作为一种靶向σ-1受体的快速起效抗抑郁药是一个有前景的候选药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验